Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
Status:
Completed
Trial end date:
2002-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with
Epstein-Barr virus-associated primary CNS lymphoma and AIDS.